Revance Logo
COMPANYPRODUCTS AND PIPELINEINVESTORSCAREERSIN THE NEWSCONTACT US
ABOUTLEADERSHIPBOARDPARTNERSHIPS
SUSTAINABILITYMEDICAL EDUCATIONAL GRANTSINVESTIGATOR SPONSORED TRIALS
Company
INVESTOR RELATIONSPRESS RELEASESEVENTS + PRESENTATIONSFINANCIALS & FILINGSCORPORATE GOVERNANCE
STOCK INFORMATIONANALYST COVERAGEINVESTOR FAQSCONTACT US
Investors
OPPORTUNITIESCULTUREBENEFITS
Careers
COMPANYPRODUCTS AND PIPELINEINVESTORSCAREERSIN THE NEWSCONTACT US
Facebook logoInstagram logoTwitter logoLinkedIn logo
1222 Demonbreun St
20th Floor
Nashville, TN 37203
+1 (510) 742-3400
LoginContact Revance
Back
March 5, 2016
Revance Announces Late-Breaking Podium Presentation of Positive 6-Month Duration Results for BELMONT Phase 2 Active Comparator Study of Injectable RT002 at the 74th Annual Meeting of the American Academy of Dermatology
March 2, 2016
Revance Releases Fourth Quarter and Full Year 2015 Results
February 23, 2016
Revance to Participate in Upcoming Investor Conferences
February 17, 2016
Revance Therapeutics to Release Fourth Quarter and Full Year 2015 Financial Results Wednesday, March 2, 2016
January 7, 2016
Revance Specifies 2016 Clinical Program Milestones
December 23, 2015
Revance Announces Positive Phase 2 Results for RT001 Botulinum Toxin Type A Topical Gel to Treat Axillary Hyperhidrosis
December 14, 2015
Revance Appoints Abhay Joshi, PhD, as Chief Operating Officer
November 19, 2015
Revance Therapeutics to Participate in the 27th Annual Piper Jaffray Healthcare Conference
November 9, 2015
Revance Therapeutics Releases Third Quarter 2015 Results
November 9, 2015
Revance Therapeutics Announces Closing of Public Offering of Common Stock
Displaying 231 - 240 of 298